Metraipolis › archive › dc_64d668ea5720

Clinical utility of neurofilament light chain as a biomarker for disease onset and progression in hereditary transthyretin amyloidosis — Europe PMC PMID:41132872

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41132872
DOI
10.3389/fneur.2025.1660344
License (as archived)
solo-consultazione
Archived
2026-11-09T11:38:18.299Z
SHA-256 of the archived text
8206309606a20b9ce2754308b83b2274b06e1ccdb7a38802a2e2b7c0b8d1bd21
Stable URL of this page
https://metraipolis.com/documento/dc_64d668ea5720

How to cite

Clinical utility of neurofilament light chain as a biomarker for disease onset and progression in hereditary transthyretin amyloidosis — Europe PMC PMID:41132872 — Europe PMC (en), https://europepmc.org/article/MED/41132872 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_64d668ea5720 (Metraipolis archive dc_64d668ea5720, sha256 8206309606a20b9ce2754308b83b2274b06e1ccdb7a38802a2e2b7c0b8d1bd21)
BibTeX
@misc{dc64d668ea5720,
  title = {Clinical utility of neurofilament light chain as a biomarker for disease onset and progression in hereditary transthyretin amyloidosis — Europe PMC PMID:41132872},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41132872},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_64d668ea5720; sha256 8206309606a20b9ce2754308b83b2274b06e1ccdb7a38802a2e2b7c0b8d1bd21},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41132872. Agents can read the archived copy with the MCP tool read_document.